(Q34470578)

2 August 2017

title

Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. (English)

1 reference

2 August 2017

1 reference

1 reference

4

Stanislas Pol

1 reference

2 August 2017

author name string

Maryline Mancini-Bourgine

1

1 reference

2 August 2017

Héléne Fontaine

2

1 reference

2 August 2017

Christian Bréchot

3

1 reference

2 August 2017

Marie-Louise Michel

5

1 reference

2 August 2017

language of work or name

English

0 references

publication date

18 August 2005

1 reference

2 August 2017

1 reference

2 August 2017

volume

24

1 reference

2 August 2017

issue

21

1 reference

2 August 2017

page(s)

4482-4489

1 reference

Hepatitis B virus infection

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

The treatment of chronic viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Lamivudine as initial treatment for chronic hepatitis B in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Hepatitis B virus immunopathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

DNA-based immunization against the envelope proteins of the hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.013

10.1016/J.VACCINE.2005.08.013

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference